<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123523</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/08</org_study_id>
    <nct_id>NCT03123523</nct_id>
  </id_info>
  <brief_title>Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes.</brief_title>
  <acronym>FABRY-Image</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anderson-Fabry disease is a genetic lysosomal storage disease, linked to chromosome X (gene
      GLA), responsible of enzyme synthesis deficit in α-galactosidase A with intracellular
      sphingolipids accumulation and multiorganic achievement.

      If renal complication is principally responsible of the pejorative evolution of the disease,
      it may also exist a cardiac achievement, symptomatic or not (heart failure symptoms including
      dyspnea, conduction abnormalities, supra-ventricular and ventricular arrhythmias), with or
      without left ventricular hypertrophy (LVH).

      Administration of agalsidase-α or ß, a genetic engineering synthetic equivalent of the
      deficient enzyme, should significantly slow disease evolution indeed reduce LVH.

      Some patients with Fabry disease without LVH should present, compared to healthy subjects,
      indirect early markers of intramyocyte lipid overload:

        -  in echocardiography, longitudinal myocardial deformation (strain) should be altered
           while ejection fraction is preserved, and

        -  in cardiac MRI, T1 mapping should be reduced1. This was also previously demonstrated in
           Fabry patients with LVH2. However, are these abnormalities of longitudinal deformation
           in echocardiography and of T1 mapping in MRI correlated to the presence of pejorative
           cardiac markers (such as clinical and functional tolerances, Brain Natriuretic Peptide
           (BNP) level and electrical complications)?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Anticipated">April 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>Dyspnea, angor, syncope and lipothymia, palpitations, heart failure signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker : poor blood pressure adaptation to exercise</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker: max level achieved</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker : percentage of theoretical maximal heart rate</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker : peak of Oxygen uptake (VO2)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker : percentage of expected peak VO2</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic exercise test marker : Expiratory volume / carbon dioxide production (VE/VCO2)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological marker : BNP elevation</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical markers at ECG and Holter ECG</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of conduction troubles; supra-ventricular and ventricular arrhythmias.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Patients group</arm_group_label>
    <description>35 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>20 healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography at T0</intervention_name>
    <arm_group_label>Patients group</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Exercise test</intervention_name>
    <arm_group_label>Patients group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological assays</intervention_name>
    <description>Creatinin, hematocrit and BNP assays</description>
    <arm_group_label>Patients group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI with contrast agent injection</intervention_name>
    <description>With injection of gadolinium</description>
    <arm_group_label>Patients group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI without contrast agent injection</intervention_name>
    <description>Without injection of gadolinium</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography at M24</intervention_name>
    <arm_group_label>Patients group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - The 35 patients will be selected from Dr Réant (Cardiologist) and Dr Rooryck-Thambo's
        (Genetician) consultations, co-responsible of the Regional Competence Centre in Inherited
        Cardiomyopathies (Bordeaux, france) and from a medical specialized group following
        regularly these patients (Dr Valérie de Précigout in Nephrology at Bordeaux Pellegrin
        Hospital, Pr Cyril Goizet and Pr Didier Lacombe in Genetics at Bordeaux Pellegrin
        Hospital).

        Inclusion will be performed according to current management and follow-up recommendations.

        - The 20 healthy volunteers will be recruited form a local database (&quot; HSync Study &quot; of Dr
        Cornolle). Their consent will be requested at inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients group :

          -  Adults (age ≥18 years), male and female.

          -  Patients diagnosed genetically having Fabry disease, with or without clinical cardiac
             symptoms and with different evolution stades of the disease.

          -  For female in age of procreation, efficient contraception will be required and a
             negative pregnancy test.

          -  Oral agreement of the patient after having read information note.

          -  Patient affiliated to social national Security registry.

        Healthy volunteers group:

          -  Adults (age ≥18 years), male and female.

          -  Unscathed of cardiovascular pathologies and cardiovascular risk factors.

          -  For female in age of procreation, efficient contraception will be required and a
             negative pregnancy test.

          -  Oral agreement of the patient after having read information note.

          -  Patient affiliated to social national Security registry.

        Exclusion Criteria:

        For the 2 groups :

          -  Extracardiac pathology limiting life expectancy &lt;1 year (cancer).

          -  Pregnant or breastfeeding female.

          -  Claustrophobia.

          -  Mechanical prosthetic valve.

          -  Severe obesity &gt; 140 kg

          -  Patients with intracardiac device (implantable cardiac defibrillator, pace maker,
             resynchronisation), surgical clips not MRI compatible, neurosensorial stimulators,
             cochlear implants, ferromagnetic foreign bodies (ocular, cerebral), neurosurgical
             derivation valves)

          -  Impossibility to provide consent or refusal to sign the consent form.

        For the patients:

        - Previous history of hypersensitivity to gadolinium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Réant patricia, MD</last_name>
    <phone>(0)5 57 65 64 85</phone>
    <phone_ext>+33</phone_ext>
    <email>patricia.reant@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carpentier Céline</last_name>
    <phone>(0)5 57 65 61 68</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.carpentier@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réant Patricia, MD</last_name>
      <phone>(0)5 57 65 64 85</phone>
      <phone_ext>+33</phone_ext>
      <email>patricia.reant@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carpentier Céline</last_name>
      <phone>(0)5 57 65 61 68</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.carpentier@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Réant Patricia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lafitte Stéphane, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reynaud Amélie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cornolle Claire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

